Current options for vaccine delivery systems by mucosal routes

被引:53
作者
Mestecky, J
Moldoveanu, Z
Michalek, SM
Morrow, CD
Compans, RW
Schafer, DP
Russell, MW
机构
[1] EMORY UNIV, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA
[2] ZYNAXIS INC, MALVERN, PA 19355 USA
基金
美国国家卫生研究院;
关键词
mucosal immunity; vaccines; vaccine delivery systems; vectors; microspheres; liposomes;
D O I
10.1016/S0168-3659(97)00036-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Infectious diseases continue to be the leading cause of morbidity and mortality worldwide. Increased awareness of the fact that mucosal membranes are the most frequent portals of entry of pathogenic microorganisms has prompted studies aimed at the development of vaccination protocols and antigen delivery systems that would lead to an increased protection of mucosae. Although systemic and strictly local (e.g., intravaginal or conjunctival) immunizations are of limited effectiveness in the induction of generalized mucosal protection, ingestion or inhalation of antigens results in a disseminated immune response manifested by the appearance of specific antibodies of the secretory immunoglobulin (Ig) A isotype in external secretions due to the dissemination of IgA precursor cells from IgA-inductive lymphoid tissues. Furthermore, additional inductive sites strategically positioned at the opening of the respiratory and digestive tracts may also be suitable targets for induction of immune responses at desired effector sites. To prevent degradation and increase the absorption of ingested antigens, novel strategies including enclosure of antigens in biodegradable microspheres or liposomes, or their expression in viral and bacterial vectors and in plants, are currently being considered. Forthcoming technological advances in antigen preparation and routes of delivery will undoubtedly have a profound impact on immunization practices in the future. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:243 / 257
页数:15
相关论文
共 110 条
[1]   HUMAN DYSTROPHIN EXPRESSION IN MDX MICE AFTER INTRAMUSCULAR INJECTION OF DNA CONSTRUCTS [J].
ACSADI, G ;
DICKSON, G ;
LOVE, DR ;
JANI, A ;
WALSH, FS ;
GURUSINGHE, A ;
WOLFF, JA ;
DAVIES, KE .
NATURE, 1991, 352 (6338) :815-818
[2]  
ALLEY CD, 1988, B LYMPHOCYTES HUMAN, P222
[3]  
ALMOND JW, 1990, SEMIN VIROL, V1, P11
[4]   ATTENUATED MENGO-VIRUS AS A VECTOR FOR IMMUNOGENIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GLYCOPROTEIN-120 [J].
ALTMEYER, R ;
ESCRIOU, N ;
GIRARD, M ;
PALMENBERG, A ;
VANDERWERF, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :9775-9779
[5]   MURINE CYTOTOXIC T-CELL RESPONSE SPECIFIC FOR HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN-B (GB) INDUCED BY ADENOVIRUS AND VACCINIA VIRUS RECOMBINANTS EXPRESSING GB [J].
BERENCSI, K ;
RANDO, RF ;
DETAISNE, C ;
PAOLETTI, E ;
PLOTKIN, SA ;
GONCZOL, E .
JOURNAL OF GENERAL VIROLOGY, 1993, 74 :2507-2512
[6]   PROTECTIVE IMMUNITY TO ROTAVIRUS-INDUCED DIARRHEA IS PASSIVELY TRANSFERRED TO NEWBORN MICE FROM NAIVE DAMS VACCINATED WITH A SINGLE DOSE OF A RECOMBINANT ADENOVIRUS EXPRESSING ROTAVIRUS VP7SC [J].
BOTH, GW ;
LOCKETT, LJ ;
JANARDHANA, V ;
EDWARDS, SJ ;
BELLAMY, AR ;
GRAHAM, FL ;
PREVEC, L ;
ANDREW, ME .
VIROLOGY, 1993, 193 (02) :940-950
[7]  
BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13
[8]  
BRANDTZAEG P, 1992, ADV OTO-RHINO-LARYNG, V47, P64
[9]  
BURNETTE WN, 1992, NEW BIOL, V4, P269
[10]   IGA COMMITMENT - MODELS FOR B-CELL DIFFERENTIATION AND POSSIBLE ROLES FOR T-CELLS IN REGULATING B-CELL DEVELOPMENT [J].
CEBRA, JJ ;
CEBRA, ER ;
CLOUGH, ER ;
FUHRMAN, JA ;
KOMISAR, JL ;
SCHWEITZER, PA ;
SHAHIN, RD .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1983, 409 (JUN) :25-38